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1. Introduction
Brain metastasis occurs with a fairly high frequency, in 25–35% of cancer patients [1]. Be‐
cause brain metastasis  directly affects  prognosis,  quality of  life  (QOL),  and performance
status  (PS),  treatment  is  crucial.  Survival  time is  reported to  be  1  month in  the  case  of
untreated brain metastasis [2], 2 months with steroid treatment alone [3], and 3-6 months
with whole-brain radiotherapy (WBRT) [4-7].  This  shows that  brain metastasis  is  a  seri‐
ously life-threatening condition.  Therapeutic  approaches have become more varied with
the  appearance  of  stereotactic  radiosurgery  (SRS),  and  establishment  of  multiple  treat‐
ment plans has become possible.  In addition to surgical resection (SR),  WBRT, and SRS,
systemic chemotherapy (SC) is also an option. The ideal treatment is to control the brain
metastasis  and prevent destruction of  the central  nervous system using combinations of
these therapeutic approaches. Among these multiple approaches, SR is effective in that it
enables  treatment  of  large  tumors  and early  improvement  of  symptoms,  which  are  not
possible with other approaches.  The indications for SR are expanded with the early im‐
provement of symptoms, leading particularly to improved QOL from the palliative view‐
point.  However,  SR  is  also  highly  invasive  compared  with  other  treatments,  and  the
indications are strict.  The standard surgical indication is single brain metastasis, and pa‐
tients with fairly good prognosis, such as those with good general condition, are selected
[8]. Recently, however, partly as a result of advances in imaging, the number of cases of
multiple brain metastases has been trending upward. This means that there are patients
in whom SR is excluded as an indication because of findings for multiple brain metasta‐
ses, and who cannot obtain the benefits of surgery. We provide aggressive treatment us‐
ing  the  same  surgical  indications  for  cases  of  multiple  brain  metastases  as  for  single
metastasis. The present study therefore investigated treatment outcomes and reported on
the effectiveness of SR for multiple brain metastases.
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2. Methods
Subjects were 100 patients with brain metastasis who underwent craniotomy and surgical
removal of tumors in the Department of Neurosurgery at Kinki University Hospital between
2004 and 2011. They included 54 patients with single brain metastasis and 46 with multiple
brain metastases. Details are shown in Table 1.
Characteristic Single Multiple
No. of cases 54 46
Age (mean) 63.3 61.3
Range 39-81 46-81
Male-to-female ratio 31:23 22:24
Primary site
Lung 29 22
Breast 9 13
Rectum 2 3
Colon 3 1
Kidney 2 1
Other 9 6
RPA classification
I 18 10
II 21 12
III 15 24
Size (mm, mean) 34.1 28.7
Table 1. Clinical characteristics of patients with single and multiple brain metastases
Surgical indications are shown in Figure 1, and treatments following surgery were done in
close conference with departments related to cancer, such as the Department of Radiation
Oncology and the Department of Medical Oncology. Each case was treated using a tailor-made
approach.
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Figure 1. Therapeutic strategies in brain metastases
The basic surgery was en bloc resection, with resection of a single site even in cases of multiple
metastases. During removal, we used fluorescence-guided surgery using fluorescein sodium
with transformation to a solid-type tumor by hydrofiber dressing for cystic lesions [9-11]. In
comparing survival time, duration of survival from the day of surgery until death was obtained
using the Kaplan-Meier method, and significant differences were determined with the log-
rank test. For all tests, a significance level of 5% was applied.
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3. Results
Among the 100 patients, gross total resection was performed in 89%. Reasons for sub-total re‐
section were invasion into blood vessels or dura mater, huge tumor size, or tumor involving an
eloquent area. Follow-up treatments are shown in Figure 2. SC was also performed in 45 cases.
Figure 2. Postoperative treatments. Concurrent systematic chemotherapy was used in 45% of cases.
Central nervous system death occurred in 9% and 6 patients died within 3 months of surgery.
Three of these patients showed exacerbation of the primary cancer and three showed poor
control of brain metastases. For all 100 patients median survival time (MST) was 9.3 months,
the 1-year survival rate was 45%, the 2-year survival rate was 10%. A comparison of single and
multiple metastases is shown in Table 2.
Single Multiple
Median survival time (mo) 9.8 8.1
1- year survival rate (%) 44 46
2- year survival rate (%) 11 9
Table 2. Survival rate of single and multiple metastases
In this comparison by number of metastases, no significant differences were seen in survival
time, including 1-year survival rate, 2-year survival rate, or MST (Fig. 3).
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Figure 3. Comparison of survival times with single and multiple brain metastases. No statistically significant difference
was confirmed between the 2 groups (p=0.296).
In a comparison by number of metastases in patients with multiple metastases, no significant
difference in survival time was seen between patients with 2-3 metastases (MST, 8.8 months;
n=32) and those with ≥4 metastases (MST, 8.0 months; n=14) (Fig. 4).
Figure 4. Comparison of survival times according to number of metastases in cases of multiple brain metastases. No
statistically significant difference was confirmed between the 2 groups (p=0.149).
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In addition, new pathological findings were revealed through pathological diagnosis obtained
with SR, and the treatment strategy was changed in some cases. The case of a typical patient
is described below.
This patient was a 49-year-old woman who was undergoing chemotherapy for lung cancer
(adenocarcinoma). SC was continued for 4 courses, when she was switched to best supportive
care because of a lack of efficacy. In screening tests for headache and visual impairment, six
brain metastases were seen. At this point, multiple metastases to other organs were identified
and she was expected to live less than 3 months (Fig. 5A-C).
Figure 5. A) Contrast-enhanced MRI findings before treatment. A total of six metastases are seen, including a lesion
≥4 cm in diameter with ventricular invasion in the right occipital lobe. (B,C) Preoperative FDG-PET examination. Multi‐
ple metastases are seen in the lungs. (D) Contrast-enhanced MRI after treatment. All of the multiple lesions have dis‐
appeared. (E,F) FDG-PET examination following systemic chemotherapy. The lesions in the lungs are markedly reduced
in size.
Headache associated with increased intracranial pressure is difficult to treat, and SR was
performed for the right occipital lobe lesion with the aim of relieving symptoms. Symptoms
rapidly improved after surgery, and the pathological diagnosis was small cell cancer. Initially,
the diagnosis had been adenocarcinoma based on adenocarcinomatous tissue obtained from
bronchoscopic biopsy of the primary lung cancer. In fact, however, the tumor represented
mixed-type lung cancer with small cell cancer, and these brain metastases was thought to
represent a recurrence of the small cell cancer. WBRT was performed postoperatively and SC
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was applied using the approach used for small cell lung cancer. A marked decrease in systemic
lesions was seen (Fig. 5D-F). Ultimately, the patient survived 19 months after surgery. This
patient obtained a greater-than-expected benefit from surgery.
4. Discussion
Various biases are inherent in the treatment for brain metastasis, according to factors such as
the primary cancer or general condition. Moreover, because of the problem of brain function,
establishing a treatment plan can be difficult. In such circumstances, many reports with a fairly
high evidence level have described results for single brain metastasis. Reports on level I include
those of Patchell et al. [12] and Noordijk et al. [13] in the 1990s. SR + WBRT was established
for single brain metastasis based on these reports. In a report by Bindal et al. [14], SR for
multiple brain metastases was seen to be effective only in cases when all of the multiple brain
metastases could be removed. However, when all lesions could not be removed, no significant
difference was seen compared with WBRT alone, and SR was not considered effective. Based
on these findings, the priority came to be placed on WBRT monotherapy in cases of multiple
brain metastases, but treatment later diversified with active SRS intervention for brain
metastasis and in 1999 Kondziolka et al. [15] reported WBRT + SRS combination radiotherapy
for cases of multiple brain metastasis. With this approach, significantly longer survival times
were obtained compared with WBRT alone, and WBRT + SRS became the general therapy for
multiple brain metastases. In 2006, Aoyama et al. [16] also reported the efficacy of SRS
monotherapy for brain metastasis with ≤4 lesions. Various treatment strategies have thus been
reported, including not only conventional WBRT, but also combination with SRS and SRS
monotherapy. Recent reports have also suggested the efficacy of SC for multiple brain
metastases [17]. Up to this time, there has been little recognition of the efficacy of SC for brain
metastasis. A response rate of 60% has been reported, but the effect is temporary and MST is
less than 6 months in the majority of cases [18-20]. However, striking advances have recently
been made in SC, with the emergence of molecularly targeted drugs as a major breakthrough.
Drugs for lung cancer include gefitinib and erlotinib. The response rate to erlotinib is in cases
of brain metastasis with EGFR mutation, showing very high efficacy. In breast cancer, the
appearance of lapatinib is also reported to be effective against brain metastasis. SC will thus
likely become necessary as one therapeutic approach in brain metastasis, particularly for
patients with multiple brain metastases.
As mentioned above, various therapeutic approaches can be used for brain metastasis,
including SR, WBRT, SRS, and SC, and various combinations. In this situation, at our hospital,
we do not consider it necessary to select treatment based on the number of metastases, such
as single or multiple, and aggressively perform SR in cases of multiple metastases just as in
cases of single metastasis. Likewise in follow-up treatment, we implement tailor-made
treatment strategies matched to the individual patients. The results have shown no differences
in either MST or survival rate depending on the number of metastases, and good treatment
outcomes have been obtained in cases of multiple brain metastases. Today, when various
therapeutic approaches are available, performing SR to eliminate lesions at an early stage is
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highly effective. Early improvement of symptoms leads to improved PS and QOL, producing
new treatment opportunities. In addition, early elimination of brain metastatic lesions reduces
the steroid dosage as well as the possibility of radiation necrosis. The result is thought to lead
ultimately to longer survival times. In our investigation, prognosis tended to be better for the
group with fewer brain metastases (2-3 lesions), but the difference did not reach the level of
statistical significance. This suggests that there is no correlation between prognosis and the
number of metastases, including even single brain metastases. This is also supported by the
low probability of central nervous system death. The total number of patients in this study
was low (100 patients) and it was not a randomized controlled trial, so the results of evaluation
are not definitive. However, the advances in cancer treatment in recent years may necessitate
a rethink of the policy of determining treatment plans based on the number of metastases.
5. Conclusions
The efficacy of SR in multiple brain metastases was investigated. Survival time and sur‐
vival rate were not significantly different compared with single brain metastasis, and no
significant difference was seen in a comparison of survival time according to number of
metastases.  The  reasons  are  thought  to  be  that  tailor-made  therapeutic  strategies  using
the multimodalities advanced in recent years are effective. It may be time to rethink the
approach  of  determining  treatment  plans  based  on  the  number  of  metastases  in  thera‐
peutic strategies for brain metastases.
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